|
Fosinopril
|
A phosphinic acid-containing angiotensin-converting enzyme inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat. (PubChem) Pharmacology: Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. By blocking ACE, Fosinopril decreases angiotensin II which is a vasoconstrictor. Fosinopril is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Mechanism of action: Fosinoprilat, the active metabolite of fosinopril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Fosinoprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin. Drug type: Approved. Small Molecule. Drug category: Angiotensin-converting Enzyme Inhibitors. Antihypertensive Agents
|
ILX:0104378
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fosphenytoin
|
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. Pharmacology: Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. Following parenteral administration of fosphenytoin, fosphenytoin is converted to the anticonvulsant phenytoin. For every mmol of fosphenytoin administered, one mmol of phenytoin is produced. The pharmacological and toxicological effects of fosphenytoin include those of phenytoin. Mechanism of action: Fosphenytoin is a prodrug of phenytoin and accordingly, its anticonvulsant effects are attributable to phenytoin. Phenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. By promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses. Loss of post-tetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas. Drug type: Approved. Small Molecule. Drug category: Anticonvulsants
|
ILX:0104379
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fourth cervical spinal ganglion
|
The fourth cervical dorsal root ganglion (or spinal ganglion; also known as a posterior root ganglion) is a cluster of sensory neuron cell bodies (a ganglion) associated with the fourth cervical spinal nerve.
|
ILX:0104380
|
13
|
FDI Lab - SciCrunch.org
|
06/01/2022
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fourth ventricle
|
Part of the ventricular system of the brain, forming a single large irregularly shaped cavity located on the midline of the rhombencephalon, between the medulla, pons and the isthmus ventrally and the cerebellum dorsally. It is continuous with the cerebral aqueduct anteriorally and the central canal of the spinal cord posteriorly. It communicates with the subarachnoid space through its lateral and median apertures.
|
ILX:0104381
|
13
|
FDI Lab - SciCrunch.org
|
01/17/2023
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fourth ventricle of WHS11
|
Delineation of the fourth ventricle of Waxholm mouse brain atlas, as seen in T2* and T2W volumes. Segmentation is based on intensity: region shows high intensity signal. Current segmentation also includes the cerebral aqueduct.
|
ILX:0104382
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fovea
|
A depression in the inner retinal surface within the macula lutea, the photoreceptor layer of which is entirely cones and which is specialized for maximum visual acuity
|
ILX:0104383
|
10
|
FDI Lab - SciCrunch.org
|
06/23/2020
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Foville Syndrome
|
Anatomical location: Pons - Unilateral lesion in the dorsal pontine tegmentum in the caudal third of the pons; Vasculature: Basilar artery, Paramedian and Short circumferential branches; Symptoms: contralateral - weakness in upper and lower extremity - ipsilateral: weakness in entire side of face, as well as lateral gaze weakness
|
ILX:0104384
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
FP receptor
|
|
ILX:0104385
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fraction collection instrument
|
|
ILX:0104386
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fraction Group Description
|
The user defined description for the fraction group.
|
ILX:0104387
|
4
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fraction Group Number
|
Identification number of the Fraction Group. The value of Fraction Group Number (300A,0071) shall be unique within the RT Plan in which it is created.
|
ILX:0104388
|
4
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fraction Group Sequence
|
Sequence of Fraction Groups in current Fraction Scheme.
|
ILX:0104389
|
6
|
FDI Lab - SciCrunch.org
|
08/28/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
troy sincomb |
|
Fraction Group Summary Sequence
|
Sequence describing current state of planned vs. delivered fraction groups.
|
ILX:0104390
|
6
|
FDI Lab - SciCrunch.org
|
08/28/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
troy sincomb |
|
Fraction Group Type
|
Indicates type of fraction group.
|
ILX:0104391
|
5
|
FDI Lab - SciCrunch.org
|
08/28/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
troy sincomb |
|
Fraction Number
|
Fraction Number of fraction during which image was acquired, within Fraction Group referenced by Referenced Fraction Group Number (300C,0022) within RT Plan referenced in Referenced RT Plan Sequence (300C,0002).
|
ILX:0104392
|
4
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fraction Pattern
|
String of 0s (no treatment) and 1s (treatment) describing treatment pattern. Length of string is 7 x Number of Fraction Pattern Digits Per Day x Repeat Fraction Cycle Length. Pattern shall start on a Monday.
|
ILX:0104393
|
4
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fraction Status Summary Sequence
|
Sequence describing status of fractions in Fraction Group.
|
ILX:0104394
|
5
|
FDI Lab - SciCrunch.org
|
08/28/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
troy sincomb |
|
Fractured
|
|
ILX:0104395
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fragile
|
|
ILX:0104396
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |
|
Fragile X mental retardation protein
|
Fragile X mental retardation 1 protein (632 aa, ~71 kDa) is encoded by the human FMR1 gene. This protein may be involved in mRNA transport. From NCI Thesaurus.
|
ILX:0104397
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/08/2016 |
0 |
NeuroLex |
NeuroLex |